Antibody-mediated gastrointestinal dysmotility in scleroderma

Gastroenterology

Volumn 123, Issue 4, 2002, Pages 1144-1150

  Goldblatt, Fiona ^a   Gordon, Tom P ^a   Waterman, Sally A ^a  

^a FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL L TYPE; CARBACHOL; IMMUNOGLOBULIN G; MUSCARINIC AGENT; MUSCARINIC M3 RECEPTOR; NEUROKININ 1 RECEPTOR AGONIST; NEUROKININ 2 RECEPTOR AGONIST; NICARDIPINE; TACHYKININ; TACHYKININ RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ARTICLE; AUTOIMMUNE DISEASE; CHANNEL GATING; CHOLINERGIC NERVE CELL; CLINICAL ARTICLE; CONTROLLED STUDY; GASTROINTESTINAL DISEASE; GASTROINTESTINAL MOTILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; INHIBITION KINETICS; INTESTINE CONTRACTION; INTESTINE MOTILITY; MALE; MOUSE; NERVE CELL EXCITABILITY; NEUROTRANSMISSION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SCLERODERMA; SJOEGREN SYNDROME; VOLTAGE CLAMP;

EID: 0036787341     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2002.36057     Document Type: Article

References (30)

1. Rose S, Young MA, Reynolds JC. Gastrointestinal manifestations of scleroderma. Gastroenterol Clin North Am 1998;27:563-594.
2. Rees WD, Leigh RJ, Christofides ND, Bloom SR, Turnberg LA. Interdigestive motor activity in patients with systemic sclerosis. Gastroenterology 1982;83:575-580.
3. Cohen S, Fisher R, Lipshutz W, Turner R, Myers A, Schumacher R. The pathogenesis of esophageal dysfunction in scleroderma and Raynaud's disease. J Clin Invest 1972;51:2663-2668.
4. Treacy W, Baggenstoss A, Slocumb C, Code C. Scleroderma of the esophagus: a correlation of histologic and physiologic findings. Ann Intern Med 1963;59:351-356.
5. Battle WM, Snape WJ Jr, Wright S, Sullivan MA, Cohen S, Meyers A, Tuthill R. Abnormal colonic motility in progressive systemic sclerosis. Ann Intern Med 1981;94:749-752.
6. Howe S, Eaker EY, Sallustio JE, Peebles C, Tan EM, Williams RC Jr. Antimyenteric neuronal antibodies in scleroderma. J Clin Invest 1994;94:761-770.
7. Furness JB. Types of neurons in the enteric nervous system. J Auton Nerv Syst 2000;81:87-96.
8. Kuriyama H, Kitamura K, Itoh T, Inoue R. Physiological features of visceral smooth muscle cells, with special reference to receptors and ion channels. Physiol Rev 1998;78:811-920.
9. Bacman S, Perez Leiros C, Sterin-Borda L, Hubscher O, Arana R, Borda E. Autoantibodies against lacrimal gland M3 muscarinic acetylcholine receptors in patients with primary Sjögren's syndrome. Invest Ophthalmol Vis Sci 1998;39:151-156.
10. Bacman S, Sterin-Borda L, Camusso JJ, Arana R, Hubscher O, Borda E. Circulating antibodies against rat parotid gland M3 muscarinic receptors in primary Sjögren's syndrome. Clin Exp Immunoi 1996;104:454-459.
11. Waterman SA, Gordon TP, Rischmueller M. Inhibitory effects of muscarinic receptor autoantibodies on parasympathetic neurotransmission in Sjögren's syndrome. Arthritis Rheum 2000;43: 1647-1654.
12. Goin JC, Sterin-Borda L, Bilder CR, Varrica LM, Iantorno G, Rios MC, Borda E. Functional implications of circulating muscarinic cholinergic receptor autoantibodies in chagasic patients with achalasia. Gastroenterology 1999;117:798-805.
13. American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23:581-590.
14. Vitali C, Bombardieri S, Moutsopoulos HM, Coll J, Gerli R, Hatron PY, Kater L, Konttinen YT, Manthorpe R, Meyer O, Mosca M, Ostuni P, Pellerito RA, Pennec Y, Porter SR, Richards A, Sauvezie B, Schiodt M, Sciuto M, Shoenfeld Y, Skopouli FN, Smolen JS, Soromenho F, Tishler M, Wattiaux MJ, and the European Study Group on Diagnostic Criteria for Sjögren's Syndrome. Assessment of the European classification criteria for Sjögren's syndrome in a series of clinically defined cases: results of a prospective multicentre study. The European Study Group on Diagnostic Criteria for Sjögren's Syndrome. Ann Rheum Dis 1996;55:116-121.
15. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA Jr, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JJ, Wilder RL, Hunder GG. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-324.
16. Nakamura R, Peebles C, Rubin R, Molder D, Tan E. Autoantibodies to nuclear antigens (ANA). Chicago: American Society for Clinical Pathology Press, 1985.
17. Steinbuch M, Audran R. The isolation of IgG from mammalian sera with the aid of caprylic acid. Arch Biochem Biophys 1969; 134:279-284.
18. Eaker EY, Kuldau JG, Verne GN, Ross SO, Sallustio JE. Myenteric neuronal antibodies in scleroderma: passive transfer evokes alterations in intestinal myoelectric activity in a rat model. J Lab Clin Med 1999;133:551-556.
19. Houzen H, Hattori Y, Kanno M, Kikuchi S, Tashiro K, Motomura M, Nakao Y, Nakamura T. Functional evaluation of inhibition of autonomic transmitter release by autoantibody from Lambert-Eaton myasthenic syndrome. Ann Neurol 1998;43:677-680.
20. Pinto A, Gillard S, Moss F, Whyte K, Brust P, Williams M, Stauderman K, Harpold M, Lang B, Newsom-Davis J, Bleakman D, Lodge D, Boot J. Human autoantibodies specific for the alpha-1A calcium channel subunit reduce both P-type and Q-type calcium currents in cerebellar neurons. Proc Natl Acad Sci U S A 1998; 95:8328-8333.
21. Boutjdir M, Chen L, Zhang ZH, Tseng CE, DiDonato F, Rashbaum W, Morris A, el-Sherif N, Buyon JP. Arrhythmogenicity of IgG and anti-52-kD SSA/Ro affinity-purified antibodies from mothers of children with congenital heart block. Circ Res 1997;80:354-362.
22. Atger M, Misrahi M, Young J, Jolivet A, Orgiazzi J, Schaison G, Milgrom E. Autoantibodies interacting with purified native thyrotropin receptor. Eur J Biochem 1999;265:1022-1031.
23. Wallukat G, Wollenberger A, Morwinski R, Pitschner HF. Anti-beta 1-adrenoceptor autoantibodies with chronotropic activity from the serum of patients with dilated cardiomyopathy: mapping of epitopes in the first and second extracellular loops. J Mol Cell Cardiol 1995;27:397-406.
24. Wallukat G, Fu HM, Matsui S, Hjalmarson A, Fu ML. Autoantibodies against M2 muscarinic receptors in patients with cardiomyopathy display non-desensitized agonist-like effects. Life Sci 1999;64:465-469.
25. Borda E, Leiros CP, Bacman S, Berra A, Sterin-Borda L. Sjögren autoantibodies modify neonatal cardiac function via M1 muscarinic acetylcholine receptor activation. Int J Cardiol 1999;70: 23-32.
26. Sterin-Borda L, Borda E. Role of neurotransmitter autoantibodies in the pathogenesis of chagasic peripheral dysautonomia. Ann N Y Acad Sci 2000;917:273-280.
27. Wallukat G, Homuth V, Fischer T, Lindschau C, Horstkamp B, Jupner A, Baur E, Nissen E, Vetter K, Neichel D, Dudenhausen JW, Haller H, Luft FC. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest 1999;103:945-952.
28. Kemp EH, Waterman EA, Hawes BE, O'Neill K, Gottumukkala RV, Gawkrodger DJ, Weetman AP, Watson PF. The melanin-concentrating hormone receptor 1, a novel target of autoantibody responses in vitiligo. J Clin Invest 2002;109:923-930.
29. Cavill D, Waterman SA, Gordon TP. Failure to detect antibodies to extracellular loop peptides of the muscarinic M3 receptor in primary Sjögren's syndrome. J Rheumatol 2002;29:1342-1344.
30. Sjogren RW. Gastrointestinal motility disorders in scleroderma. Arthritis Rheum 1994;37:1265-1282.